Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Indication

Sleep Disorders

Clinical and regulatory intelligence for Sleep Disorders with 13 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
13
Catalysts
0
Assets
9

Relevant assets

Daridorexant →
Dreem →
HETLIOZ →
Ramelteon →
Real-World →
Sterling →
Suvorexant →
TAK-360 →
UMEDICA →

Relevant companies

Micro Labs →
Sterling Pharmaceuticals Ltd →
Takeda →
UMEDICA LABS →
Vanda Pharmaceuticals →

Recent signals(13)

RegulatoryAugust 1, 2026

FDA Approves Supplement for HETLIOZ (Tasimelteon) by Vanda Pharmaceuticals

The FDA has approved a supplemental application for HETLIOZ, a drug containing tasimelteon.

ClinicalJuly 28, 2026

Takeda's TAK-360 Trial for Narcolepsy Type 1 Underway

Takeda is conducting a clinical trial to evaluate the safety and tolerability of TAK-360 in adults with Narcolepsy Type 1.

RegulatoryJuly 26, 2026

FDA Grants AP Status for Ramelteon ANDA 215243 by Micro Labs

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for Ramelteon submitted by Micro Labs.

ClinicalJuly 23, 2026

University of Maryland Evaluates Suvorexant for Reducing Drug Demand

A clinical trial is underway to assess the efficacy of suvorexant in reducing drug demand and subjective liking.

ClinicalJuly 17, 2026

Daridorexant Trial Targets Insomnia and Alcohol Use Disorder

A clinical trial is underway to evaluate daridorexant's efficacy in reducing alcohol consumption and improving sleep in patients with insomnia and alcohol use disorder.

StrategyJuly 15, 2026

UMEDICA LABS Receives FDA Approval for Zolpidem Tartrate ANDA220717

UMEDICA LABS has received an Abbreviated New Drug Application (ANDA) approval for Zolpidem Tartrate.

ClinicalJuly 11, 2026

Study on Dopaminergic Pathway in Sleep Breathing Disorders Initiated

A clinical trial is underway to investigate the role of dopamine in sleep-disordered breathing using polysomnography and genetic testing.

CompetitiveJuly 5, 2026

Real-World Study on Dong'e Brand Ejiao Yuanjiang for Sleep Improvement

A real-world study is evaluating the sleep-improving efficacy of Dong'e Brand Ejiao Yuanjiang with 66 participants over 60 days.

RegulatoryJuly 3, 2026

FDA Accepts Supplement Application for Ramelteon by Micro Labs

The FDA has accepted a supplemental application for Ramelteon submitted by Micro Labs.

StrategyJune 30, 2026

FDA Grants Approval for Ramelteon ANDA215485 by Hibrow Healthcare

The FDA has granted approval for the Abbreviated New Drug Application (ANDA) 215485 for Ramelteon submitted by Hibrow Healthcare.

RegulatoryJune 24, 2026

Sterling Pharmaceuticals recalls KidNaps Melatonin due to stability issues

Sterling Pharmaceuticals Ltd and Veriton Pharma Ltd are recalling all batches of KidNaps (Melatonin) 1mg in 1ml Oral Solution due to out of specification stability results.

ClinicalJune 23, 2026

Study on Transcranial Electrostimulation for Pain Relief in OSA Surgery

A study is investigating the efficacy of transcranial electrostimulation (TES) for postoperative pain relief in obstructive sleep apnea surgery.

ClinicalJune 21, 2026

Study on Sleep Quality Improvement with CPAP in Obstructive Sleep Apnea

A study is underway to evaluate the impact of CPAP on sleep quality over multiple nights in a home setting.

Upcoming catalysts

No catalysts indexed for this entity yet.

Therapeutic areas

Herbal Medicine →
Melatonin Receptor Agonist →
Neurology →
Obstructive Sleep Apnea →
Psychiatry →
Sleep Disorders →
Sleep-Disordered Breathing →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.